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Introduction
There has been relatively little apparent interest in the quality 
of medicines used to treat common life-threatening diseases 
despite the logical implication that poor-quality medicines 
will reduce the effectiveness of therapy and encourage drug 
resistance. Evidence suggests that a significant proportion of 
drugs consumed in the developing world are of poor quality 
[1–25]. Translating evidence on drug treatment outcomes 
into treatment policy is futile if the medicines actually 
used have substantially inferior efficacy compared with the 
medicines originally evaluated [7]. Poor-quality medicines 
are conventionally classified into three main categories: 
counterfeit, substandard, and degraded (Box 1). 
The existing literature includes little discussion about 
the most appropriate sampling and reporting strategies 
for medicine quality surveys [2,7,15,16], and the majority 
of papers either have inadequate reporting of sampling 
methods and/or used “convenience” sampling, which 
is potentially flawed by bias. Depending on whether the 
medicine collectors, consciously or subconsciously, prefer 
to find poor-quality medicines (e.g., if it might result in 
publications or funding) or not (e.g., if it might cause 
embarrassment), they may overestimate or underestimate, 
respectively, the prevalence of outlets selling poor-quality 
medicines. Convenience sampling may lead investigators to 
sample more geographically accessible outlets, which may be 
unrepresentative of those used by patients. 
This paper has two main aims. First, we discuss how 
medicine quality surveys can be conducted and how simple 
and efficient but statistically valid sampling techniques can 
be used to provide an estimate of the prevalence of outlets 
selling low-quality medicines. This discussion is based upon 
a literature review and consultation with experts in the 
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degraded medicines are major problems of global importance, 




countries, where information and drug regulation 
enforcement is scant, but inadequate infrastructure, non-
regulated drug outlets, and black market operations make 
drug quality surveys difficult. 
sÈ 7EÈREVIEWEDÈPREVIOUSÈWORKÈONÈTHEÈQUALITYÈOFÈMEDICINESÈANDÈ
how medicine quality studies have been reported. We discuss 
best sampling strategies and suggest a draft checklist of 
appropriate items to be addressed in future studies. 
sÈ -OREÈRESEARCHÈONÈMEDICINEÈQUALITYÈMONITORINGÈMETHODOLOGIESÈ
is needed, together with a standardisation of medicine 
collection protocols. The objective of the guidelines presented 
here is to guide surveys of medicine quality and how they are 
reported, and to provide a template for further development.PLoS Medicine  |  www.plosmedicine.org 0253 March 2009  |  Volume 6  |  Issue 3  |  e1000052
field (five physicians, four chemists, three pharmacists, two 
statisticians, and two public health epidemiologists), involved 
in research on poor-quality medicines (Box 2: Methods). 
Second, we discuss how such studies may be reported and 
propose a checklist (Medicine Quality Assessment Reporting 
Guidelines [MEDQUARG]) to facilitate transparent, 
consistent, and accurate reporting, in the hope that robust 
evidence will assist in improving medicine quality. A fuller 
version of this discussion document is available in Text S1.
Strategies for Conducting and Reporting Medicine 
Quality Surveys
1. Sampling techniques. Informed decisions on appropriate 
sampling size and strategies are currently very difficult as 
there are no published reliable estimates for the prevalence 
of poor-quality medicines or the proportion of outlets selling 
such medicines for any country. The sampling strategy will 
depend on the question being asked, such as “Are there 
medicines of poor quality in a particular geographical area?” 
or “Is the proportion of outlets selling poor-quality medicines 
above a pre-determined acceptable level, and/or what is the 
prevalence of poor-quality medicines in this geographical 
area?” The sampling unit(s) for analysis may be the outlets 
and/or the medicines sold from them. The distinction is 
important as, for example, an area may have one outlet 
selling 50% of the poor-quality medicine(s) bought in the 
region or ten outlets each selling 5% of the poor-quality 
medicines. Weighting may be required based on the number 
of treatments dispensed per outlet, which could be derived 
from household surveys or sales volumes declared by the 
outlets. Surveys have usually estimated the proportion of 
poor-quality medicines collected in outlets [4,10,11,14,17–
25] and not the proportion of shops selling poor-quality 
medicines. We suggest that both types of measures should 
be reported [18]. By using the proportion of medicine 
outlets selling poor-quality essential medicines as the unit 
of observation and a standardised randomised sampling 
procedure of sufficient sample size, it will be possible to map 
distribution and allow comparisons through time. 
There has been no discussion as to what proportion of 
outlets selling poor-quality medicines should be regarded as 
unacceptable. Ideally there should be zero tolerance for poor-
quality medicines as even a 1% prevalence of such medicines 
for potentially fatal diseases, such as malaria, tuberculosis, 
and HIV, is disastrous. However, as 30% of World Health 
Organization member states are said to have either “no 
medicines regulation or a capacity that hardly functions” 
[12], it is extremely unlikely that these medicines regulatory 
agencies (MRAs) will be able to reduce the prevalence 
of poor-quality medicines to less than 1%.It is currently 
recommended that national malaria treatment policy should 
be changed when about 10% of patients fail treatment [26]. 
It is therefore logical that strenuous efforts should be made 
to improve the quality of antimalarials available such that 
the proportion of outlets selling ineffective antimalarial 
medicines is less than 10%. The threshold values (see below) 
that determine what is an unacceptable proportion of outlets 
selling poor-quality medicines would presumably be higher in 
countries with good medicines regulation and should rise as 
MRAs develop capacity.
Convenience surveys, in which collectors sample medicines 
without specific guidance as to which outlets to sample, 
have been the predominant technique used. They are 
simple and relatively inexpensive and are the only sampling 
technique that does not require complete lists of outlets in 
defined areas, which may be difficult to obtain, especially for 
unlicensed or mobile outlets. However, they are inherently 
prone to biases. The results are dependent on the collector’s 
choice of outlets, and prevalence estimates can have no 
reliable associated measure of confidence. Changes in the 
prevalence of poor-quality medicines, and outlets selling 
them, through time derived from convenience sampling 
cannot be interpreted reliably as changes may simply 
represent sampling artefact. Nevertheless convenience 
surveys may provide the initial signal of a problem (analogous 
to case reports of adverse effects to a drug), and may 
provide evidence to support legal action in police and MRA 
investigations. If convenience sampling does indicate a drug 
quality problem, we suggest that more objective methods be 
used in subsequent surveys. If the sampling suggests that drug 
quality is good, this may be a false negative result.
A more objective technique is random sampling, which 
with sufficient sample sizes will give reliable estimates of the 
prevalence of outlets selling poor-quality medicines and their 
distribution in the defined area [27,28]. However, there 
are only three published studies in which random sampling 
has been used [22–25]. A random survey can be stratified 
by geographical, trade, and socioeconomic variables. 
Comparisons with subsequent estimates are valid and will 
allow the evaluation of interventions. The disadvantages of 
random sampling are the large sample sizes needed and the 
associated costs. It is important that a true randomisation 
Box 1. Definitions
A counterfeit medicine is “deliberately and fraudulently 
mislabelled with respect to identity and/or source. 
Counterfeiting may include products with the correct 
ingredients or with the wrong ingredients, without active 
ingredients, with insufficient active ingredient or with fake 
packaging” [11].
Substandard medicines “are genuine medicines produced 
by legitimate manufacturers that do not meet the quality 
specifications that the producer says they meet. For example, 
they may contain less (or more) active ingredient than written 
on the package. This may not be an intention to cheat, but may 
be due to problems with the manufacturing process”[12].
Degraded medicines may result from exposure of good-quality 
medicines to light, heat, and humidity. It can be difficult to 
distinguish degraded medicines from those that left the factory 
as substandard, but the distinction is important as the causes 
and remedies are different [13]. 
In addition, medicines used past their expiry date should also 
be regarded as poor quality—as they may also be degraded. 
However, there are very few data on what the expiry date 
for medicines used in the tropics should be, rather than the 
conventional three years. More investigation is required—three 
years may well be too short, or too long, for some medicines. If 
medicines can be used for longer after the conventional expiry 
date this would have important economic and drug safety 
benefits.
In many reports it is unclear whether a poor-quality medicine is 
counterfeit, substandard, or degraded.PLoS Medicine  |  www.plosmedicine.org 0254 March 2009  |  Volume 6  |  Issue 3  |  e1000052
procedure is used, such as from formal random number 
tables or using simple statistical software.
Lot quality assurance sampling (LQAS), to determine 
whether the prevalence of outlets selling poor-quality 
medicines exceeds a certain threshold, may be the most 
economical first step before deciding whether a randomised 
survey is required [29–31]. LQAS was developed to 
determine whether a batch (lot) of goods met the desired 
specifications without having to inspect the entire lot (Box 
3: Example [32]). Thus, the sample size in LQAS is defined 
as the number of “units” that are selected from each lot, 
and the outcome is either “acceptable” or “unacceptable”. 
Setting the level of risk taken by not inspecting each item, 
the investigator is able to accept or reject an entire lot after 
inspecting a randomly selected sample. The sample size 
in LQAS is based on defined threshold values that classify 
good and bad outcomes and the probability of error that 
the investigators are willing to tolerate. The first step is 
to determine the upper and lower threshold values. For 
example, an area in which 20% or more of the outlets sell 
poor-quality medicines may be considered a “bad” situation 
since the risk of buying poor-quality medicines will be high, 
whereas 5% or less may be considered a “good” situation 
since the risk of buying poor-quality medicines will be lower. 
Next, acceptable probabilities of error must be specified; 
i.e., the risk of accepting a “bad” lot (“consumer risk”, Type 
I [alpha] error) and the risk of not accepting a “good” lot 
(“provider risk”, Type II [beta] error). The former is often set 
to 0.05. This means that if the null hypothesis (the defective 
goods proportion is less than the specified value) is true, 
there is a 5% chance that an unacceptable lot would be 
accepted. In general, the consumer risk is set lower than the 
provider risk. Once the threshold values and probabilities of 
error have been considered, a sample size and decision value 
can be obtained (see Box 3: Example). The decision value is 
the number of “defective” items that need to be found before 
a lot is considered unacceptable. 
LQAS still requires random (i.e., unbiased) sampling 
and has the disadvantage that it does not estimate an exact 
prevalence, but the advantage of requiring smaller sample 
sizes. Moreover, sampling can stop once the number of 
outlets with poor-quality medicine is exceeded, greatly 
reducing sampling time and costs [30]. If the number of 
outlets with poor-quality medicines exceeds the predefined 
number, further investigation with a larger random sample 
could be performed to measure the prevalence of outlets 
selling poor-quality medicines, and to examine accurately 
longitudinal changes. LQAS is relatively easily carried out and 
has been shown to give accurate and useful information that 
is translatable into policy [29–31,33–35]. 
Sentinel site monitoring involves following the quality of 
medicines at a particular locality through time [15]. There 
is no consensus as to whether these sites should be chosen 
on the basis of potentially important variables such as rural 
versus urban and private versus public outlets, nor on 
sampling methodology. Although the power of sentinel site 
monitoring resides in following longitudinal changes in one 
place, it suffers from the disadvantage that shop owners will 
probably soon realise that they are being sampled and will 
change their behaviour accordingly, and thus will no longer 
be representative of the population. 
2. Who should sample? Reports often do not state who was 
responsible for sampling medicines and how the collectors 
were chosen, and thus the likelihood that sellers would realise 
Box 2. Methods
We first searched the medical literature through PubMed, 
Google Scholar, and the World Health Organization Web site 
using the keywords “counterfeit”, substandard”, “fake”, “medicine 
quality”, and “drug quality” for information and guidance related 
to the conduct and reporting of medicines quality surveys. 
PNN, FMF, and MDG created a draft document summarising 
the literature, and PNN, SJL, LJW, and NJW contributed to 
the statistical section. We then undertook a consultation by 
circulating multiple sequential drafts (about six) to an additional 
ten people who had recently published on the subject. They 
were contacted by e-mail and asked if they would be able to 
contribute—none declined. PNN incorporated their comments 
into this consensus document, and all participated with the 
iterative process and agree with the document presented here. 
We also posted the draft document paper on the Enhancing the 
QUAlity and Transparency Of health Research (EQUATOR) network 
Web site [38] for four weeks to request comments by e-mail from 
a wider community and incorporated the response received.
Box 3: Example
There is interest in determining the prevalence of outlets selling 
poor-quality co-artemether, the national first-line recommended 
treatment for malaria, on an island called San Serriffe [27]. 
Random Sampling
We can estimate a sample size assuming a prevalence of 50% 
(or p = 0.5). This choice of estimated prevalence will give us 
the most conservative (i.e., largest) sample size needed. To 
determine the actual prevalence of outlets selling counterfeits 
with a precision of 5% (below 0.05 × 2 = 0.1) with 95% 
confidence intervals (z = 1.96), we would need a random sample 
size (n) of ~390 (n = 4p(1−p)z2/precision2 = 4 × 0.5(1−0.5 × 
(1.96)2/(0.1)2) [28, Table 6.1]. This means that purchases from 
390 different outlets selling co-artemether would be required to 
obtain an objective estimate of the prevalence of those selling 
poor-quality co-artemether at one time point in one region.
LQAS
For LQAS sampling we set our upper threshold to 95% and the 
lower threshold to 80%. This means that it is acceptable for 
95% of outlets selling artemether-lumefantrine (the unit) in one 
district (the lot) in San Serriffe to have good-quality medicines 
and unacceptable for less than 80% to have good-quality 
medicines. Then we set the Type I error to 0.05 (i.e., there is a 5 in 
100 chance that a district with 80% or fewer of the outlets selling 
good-quality drugs will go undetected) and the Type II risk to 
0.10 (i.e., there is a 10 in 100 chance that we will inappropriately 
direct resources to a district in which 95% or more of the outlets 
are in fact selling good-quality drugs). Our sample size would 
be 38 randomly selected outlets, and the district would be 
considered unacceptable if more than four outlets had poor-
quality artemether-lumefantrine (calculated using SampleLQ 
[32]). In other words, the null hypothesis that the district has at 
least 80% of its outlets selling good artemether-lumefantrine 
would be rejected if more than four out of 38 outlets sold poor-
quality artemether-lumefantrine.PLoS Medicine  |  www.plosmedicine.org 0255 March 2009  |  Volume 6  |  Issue 3  |  e1000052
that they were participating in a survey. If the seller knows 
or is concerned that his/her stock contains illegal or poor-
quality medicines and that the buyer is potentially linked 
to the MRA, this will greatly influence what medicines are 
offered for sale [36]. However, if the outlet staff are anxious 
to avoid selling poor-quality medicines, open sampling with 
feedback would allow more data to be collected and allow 
direct improvement in the medicine supply. In the face 
of uncertainty as to the sellers’ awareness, we suggest that 
mystery shoppers [37] are the appropriate collectors in most 
circumstances and that sampling be performed by nationals 
of the country concerned. They should use a scenario, stating, 
for example, that they are visiting from another part of the 
country and would like some medicines for disease X for 
reason Y for a stereotyped patient Z without stating or giving 
any indication that they are not a “normal” shopper. 
Table 1. MEDQUARG Checklist of Items That We Suggest Should Be Addressed in Reports of Surveys of Medicine Quality
Section and Topic Item Description
Title/abstract/keywords 1 Identify the article as a study of medicine quality (recommended MeSH headings: “medicine quality,  sÈ
substandard, degraded, counterfeit”)
Provide an abstract of what was done and what was found, describing the main survey methods and chemical  sÈ
analysis techniques used
Introduction 2 Summarise previous relevant drug quality information and describe the drug regulatory environment sÈ
State specific objectives sÈ
Methods
Survey details 3 The timing and location of the survey; when samples collected and when samples analysed.
Definitions 4 The definitions of counterfeit, substandard, and degraded medicines used.
Outlets 5 The type, including indices of size (e.g., turnover), of drug outlets sampled.
Sampling design 6 Sampling design and sample size calculation sÈ
Type and number of dosage units purchased/outlet sÈ
Definition of sampling frame sÈ
Question of interest, assumptions, sampling method(s) (including method of randomisation if random  sÈ
sampling used)
Samplers 7 Who carried out the sampling and in what guise? What did the collector say in buying the medicines?
Statistical methods 8 Describe the data analysis techniques used. 
Ethical issues 9 Whether ethical approval was sought and whether the study encountered any ethical issues.
Packaging 10 Packaging examination and reference standards.
Chemical analysis 11 Chemical analysis and dissolution testing SOPs and location(s) of laboratory. Description of validation and 
reference standards used.
Method validation 12 Details of laboratory method validation results, including but not limited to: Certificate of analysis for reference 
standard, within and between run repeatability (RSD% for n = 5–8), detection and quantitation limits, accuracy 
observed for reference samples, linear range for all analytes, sample preparation recovery studies, selectivity. 
Possibly, validation against a reference method or inter-laboratory study. 
Blinding 13 Whether chemistry was performed blinded to packaging and vice versa.
Results
Outlets 14 The details of the outlets actually sampled, “class” of pharmacy (e.g., public, private for profit, private not for profit, 
informal, itinerant).
Missing samples 15 The reasons why any outlets chosen for sampling did not furnish a sample. Do these outlets differ systematically 
from those in which samples were obtained?
Packaging and chemistry results 16 Packaging and chemistry results and their relationship sÈ
Details of products sampled—how many, in what drug classes, countries of origin, batch numbers,  sÈ
manufacture and expiry dates
Results for each analysis—packaging, % AI, dissolution sÈ
Additional information could be included in supplementary material  sÈ
Category of poor-quality medicine 17 A clear statement for each medicine sample detected, whether the investigators class it as genuine, counterfeit, 
substandard, or degraded, with an explanation as to why and whether the medicine was registered with the 
government in the location(s) sampled.
State company and address as given on 
packaging
18 If the names of companies and addresses not given, give a reason as to why this information is not provided. 
Sharing data with MRA 19 Whether the data shared with the appropriate MRA and IMPACT.
Dissemination 20 Description of any non-covert packaging features that would allow others to detect counterfeit medicines. If 
publication is not possible, consider disseminating via Web-based supplementary material.
Discussion
Key results 21 Summarise key results with reference to study objectives.
Limitations 22 Discussion of limitations of study, especially how robust the estimates of prevalence are and how applicable they 
may be to wider geographical areas. Discuss the direction and extent of any potential bias.
Interpretation 23 An interpretation of the results, in conjunction with prior studies, in relation to public health. 
Intervention 24 Whether interventions are thought appropriate and, if so, what type.
Other Information
Conflict of interest 25 State any potential conflicts of interest.
Funding 26 Give the source of funding and role of funders in the study.
AI, active pharmaceutical ingredient; IMPACT, International Medical Products Anti-Counterfeiting Taskforce; RSD, relative standard deviation; SOP, standard operating procedure.
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3. What, when, and how much to sample? Outlets vary 
greatly in type and may be classified according to the local 
drug law and number and training of staff. Public health 
considerations should be the main guides for which types of 
outlets and what medicines and where to sample. In resource-
poor settings, medicines sampled should be those on the 
country’s essential medicines list, emphasising the outlets 
most widely used. Surveys with the collection of a restricted 
number of samples per batch may result in errors—e.g., 
fake and genuine tablets of the antimalarial artesunate may 
have the same batch numbers [8]. As outlets may have more 
than one brand of a particular medicine available, decisions 
should be made before sampling as to which to request. If 
a selection has to be made, this should be done randomly 
(Sengaloundeth et al., unpublished data). 
A problematic issue is the number of dosage units to 
sample. Thirty dosage units for a single tablet/capsule 
medicine of a lot number from each location have been 
recommended [16]. Such a sample size gives enough dosage 
units to determine identity and content of active ingredients, 
dissolution, and degradation. However, many outlets in the 
rural tropics do not have 30 dosage units per medicine, and 
a request for such a large quantity is likely to suggest that 
the buyer is not an ordinary shopper [10,36]. We therefore 
suggest a smaller sample size of dosage units. The collection 
of between five and ten units should allow assessment but may 
not be sufficient for legal purposes. 
4. Ethical and legal aspects of sampling. Whether ethical 
review or informed consent is necessary to sample medicines 
from those selling them has not been widely debated; if 
this issue is of concern, the survey should be discussed with 
the appropriate ethical committee(s) and the affected 
communities [37]. If poor-quality medicines are detected, 
we suggest that the investigators have a duty to report the 
results to the local MRA so that they can make their own 
legal investigations and the evidence can be used to improve 
national medicine quality. 
5. Costs. Medicine quality surveys can be expensive, 
mostly because of the costs of chemical analysis, and this has 
inhibited such work with the result that we have very little 
objective information. However, given the large expense of 
clinical trials and medicines and the enormous economic 
burden of life-threatening diseases, this lack of investment is 
a false economy. More investment in laboratory infrastructure 
and personnel training is needed. It has been argued that 
surveys with random selection of outlets are not necessary, 
too complicated, or too expensive. We suggest that they are 
vital and that the additional expense in comparison to the 
chemical analysis cost is small. 
6. Reporting. The MEDQUARG guidelines (Table 1) 
consist of a checklist of items that we propose should be 
included in reports of medicine quality. These are not 
an attempt to prescribe the reporting of such research in 
a rigid format [38] and will evolve as more information 
and experience in this field becomes available. Wherever 
possible publications describing medicine quality should 
provide manufacturer’s names as stated on the packaging 
[39]. Care should be taken to avoid legal action by the stated 
manufacturer, and it is the responsibility of the authors 
to determine whether or not to take legal advice before 
publication. Suggestions made in this article do not constitute 
legal advice and may not be relied upon to replace legal 
advice. However, it is our opinion that the phrase “stated to 
be manufactured by...” can be used as a statement of fact and 
does not mean that the manufacturer stated on the packaging 
actually manufactured the product. 
Conclusions
Poor-quality medicines are a major impediment to 
improvements in public health. The quantity and quality of 
data available to those trying to improve the quality of the 
medicine supply for life-threatening diseases is woeful. We 
have discussed survey techniques to estimate the frequency 
of poor-quality medicines in geographical areas and have 
highlighted LQAS as a potentially accurate, relatively 
inexpensive, and useful screening tool for initial checking of 
whether the number of outlets selling good-quality medicines 
is acceptable. We also present a first draft of reporting 
guidelines, which we hope will be discussed and improved 
through posting of responses to this paper. The health of 
people living in developing countries is critically dependent 
upon the availability of good-quality medicines. We hope that 
this field will attract the interest and support it deserves, and 
that the recommendations made here will evolve.  
Supporting Information
Text S1. Longer version of the article 
Found at doi:10.1371/journal.pmed.1000052.sd001 (190 KB PDF). 
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